Cebaracetam

Cebaracetam is a synthetic small molecule that belongs to the racetam class, a group of compounds sharing a 2-pyrrolidinone core that has been explored for possible effects on memory and cognition ^[1]. Its structure can be described as a piperazin-2-one analogue of 4-chlorophenylpiracetam, in which the terminal amide group of the parent racetam is replaced by a piperazine ring ^[1]. The molecule carries the formula C16H18ClN3O3 and a molar mass of roughly 335.8 grams per mole, and it is catalogued in chemical databases under its systematic name and registry identifiers ^[2].

The compound was developed as a pharmaceutical research candidate during the early and middle 1990s and carried the developmental code names CGS-25248 and ZY-15119 ^[1]. It was investigated as a potential therapy for disorders of cognition, and analytical methods were published for measuring it in human biological fluids, indicating that it reached the stage of human study ^[3]. Development ultimately did not continue past phase II, and the program was recorded as discontinued in 1995 ^[1].

Published research on cebaracetam is sparse. One methodological study described a fully automated high-performance liquid chromatography assay, based on solid-phase extraction with automated cartridge exchange, for determining the drug in human urine; that work reflects the kind of pharmacokinetic characterization carried out during its clinical evaluation ^[3]. Because the program was abandoned, no large efficacy trials or long-term data sets were ever published.

Cebaracetam never received marketing approval in any jurisdiction and is not an approved medicine ^[1]. Today it exists essentially as a discontinued investigational compound and a reference entry in chemical and drug-development databases, rather than as a commercial product or a widely sold supplement ^[1][2]. No standardized consumer formulation is recognized.

There is little published human safety information for cebaracetam specifically. Racetams as a class tend to be relatively well tolerated, with headaches from cholinergic demand being a common complaint. Given the thin data, it warrants caution and careful attention to sourcing.

Cebaracetam is an experimental member of the racetam family that emerged from pharmaceutical cognition-enhancer programs of the late 1980s and early 1990s, carrying developmental code designations including N-1440 and CGS-25248. Structurally it is a substituted pyrrolidinone analogue related to the piracetam series, and it was advanced as a candidate for disorders of cognition. Developed within the Ciba-Geigy lineage that later became part of Novartis, cebaracetam progressed into phase II clinical evaluation before its development was discontinued around 1995. It was never marketed, and it remains an obscure compound known chiefly from patent and drug-pipeline records rather than any approved therapeutic use.

Cebaracetam has essentially no popular reputation and is not a fixture of the consumer nootropics market; it is an abandoned clinical candidate rather than a compound with a user following. Among the small community that catalogs racetams, it is treated as a historical curiosity: a molecule that reached mid-stage trials and then vanished, with little published human efficacy data and a mechanism of action that was never clearly established. Because it was discontinued and is not readily available, discussion of cebaracetam is largely archival, and any claims about its effects should be regarded as speculative given the absence of substantial, accessible evidence.